Drug insight: Histone deacetylase inhibitors - Development of the new targeted anticancer agent suberoylanilide hydroxamic acid

Nature Clinical Practice Oncology

Volumn 2, Issue 3, 2005, Pages 150-157

  Kelly, William Kevin ^a,b   Marks, Paul A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Apoptosis; Hematologic malignancies; Histones; Solid tumors; Thioredoxin

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 4 N ACETYLDINALINE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ARYLBUTYRIC ACID DERIVATIVE; BORTEZOMIB; CARBOXYCINNAMIC ACID BISHYDROXAMIDE; FLAVOPIRIDOL; FLUDARABINE; FR 901228; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; IMATINIB; LBH 589A; LYSINE; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; NONHISTONE PROTEIN; REGULATOR PROTEIN; TRANSCRIPTION FACTOR; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ACETYLATION; ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; CELL DEATH; CHROMATIN; CLINICAL TRIAL; DEACETYLATION; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; EPIGENETICS; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY CARCINOMA; MESOTHELIOMA; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STRUCTURE ANALYSIS; T CELL LYMPHOMA; THYROID CANCER; TREATMENT OUTCOME;

CELL DEATH; CHROMATIN; CLINICAL TRIALS; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; HISTONE DEACETYLASES; HISTONES; HUMANS; HYDROXAMIC ACIDS; NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 20444479514     PISSN: 17434254     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncponc0106     Document Type: Review

References (47)

1. Miller TA et al. (2003) Histone deacetylase inhibitors. J Med Chem 46: 5097-5116
2. Marks PA et al. (2004) Histone deacetylase inhibitors. Adv Cancer Res 91: 137-168
3. Yoshida M et al. (1990) Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265: 17174-17179
4. Kyrylenko S et al. (2003) Differential regulation of the Sir2 histone deacetylase gene family by inhibitors of class I and II histone deacetylases. Cell Mol Life Sci 60: 1990-1997
5. Remiszewski SW (2003) The discovery of NVP-LAQ824: from concept to clinic. Curr Med Chem 10: 2393-2402
6. Furumai R et al. (2002) FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 62: 4916-4921
7. Piekarz R and Bates S (2004) A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm Des 10: 2289-2298
8. Thibault A et al. (1994) A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res 54: 1690-1694
9. Chang SM et al. (1999) Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J Clin Oncol 17: 984-990
10. Reid T et al. (2004) Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer 45: 381-386
11. Atmaca A et al. (2004) A dose escalating phase I study with valproic acid (VPA) in patients with advanced cancer. ASCO Annual Meeting Proceedings (Post-Meeting Edition) [abstract #3169] J Clin Oncol 22 (Suppl)
12. Lucas DM et al. (2004) The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia 18: 1207-1214
13. Kimmel KA et al. (2001) A Phase I dose-finding study of CI-994 in combination with capecitabine in patients with advanced solid tumors. [abstract #345] Proc Am Soc Clin Oncol 87: a345
14. Wolffe AP and Pruss D (1996) Deviant nucleosomes: the functional specialization of chromatin. Trends Genet 12: 58-62
15. Luger K et al. (1997) Crystal structure of the nucleosome core particle at 2.8 Å resolution. Nature 389: 251-260
16. Jenuwein T and Allis CD (2001) Translating the histone code. Science 293: 1074-1080
17. Spotswood HT and Turner BM (2002) An increasingly complex code. J Clin Invest 110: 577-582
18. Fischle W et al. (2003) Binary switches and modification cassettes in histone biology and beyond. Nature 425: 475-479
19. Gui CY et al. (2004) Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci U S A 101: 1241-1246
20. Arts J et al. (2003) Histone deacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics. Curr Med Chem 10: 2343-2350
21. Glaser KB et al. (2003) Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem Biophys Res Commun 310: 529-536
22. Cress WD and Seto E (2000) Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 184: 1-16
23. de Ruijter AJ et al. (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370 (Part 3): 737-749
24. Jones PA and Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428
25. Johnstone RW and Licht JD (2003) Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4: 13-18
26. He LZ et al. (2001) Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 108: 1321-1330
27. Murata T et al. (2001) Defect of histone acetyltransferase activity of the nuclear transcriptional coactivator CBP in Rubinstein-Taybi syndrome. Hum Mol Genet 10: 1071-1076
28. Finnin MS (1999) Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401: 188-193
29. Gray SG et al. (2004) Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines. Int J Oncol 24: 773-795
30. Richon VM et al. (2000) Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97: 10014-10019
31. Mitsiades CS et al. (2004) Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A 101: 540-545
32. Butler LM et al. (2002) The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci U S A 99: 11700-11705
33. Warrener R et al. (2003) Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints. FASEB J 17: 1550-1552
34. Qiu L et al. (1999) Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br J Cancer 80: 1252-1258
35. Polevoda B and Sherman F (2002) The diversity of acetylated proteins. Genome Biol 3: reviews 0006
36. Kouzarides T (2000) Acetylation: a regulatory modification to rival phosphorylation? EMBO J 19: 1176-1179
37. Pei XY et al. (2004) Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 10: 3839-3852
38. Rahmani M et al. (2003) Coadministration of the heat shock protein 90 antagonist 17-allylamino-17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Res 63: 8420-8427
39. Kelly WK et al. (2003) Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9: 3578-3588
40. Duvic M et al. (2003) Phase II trial of oral suberoylanilide hydroxamic acid (SAHA) for cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL). [abstract #625] Proc Am Soc Hematol
41. Marks PA and Kelly WK Histone deacetylase inhibitors: novel targeted anti-cancer agents. In DNA Methylation Epigenetics and Metastasis. (Ed. Esteller M) Boston, Dordrecht, London: Kluwer Academic Publisher, in press
42. Ungerstedt JS et al. (2005) Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitor. Proc Natl Acad Sci U S A 102: 673-678
43. Peart MJ et al. (2003) Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 63: 4460-4471
44. Butler LM et al. (2000) Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60: 5165-5170
45. Kelly WK et al: Phase I study of the oral histone deacetylase inhibitor: suberoylanilide hydroxamic acid (SAHA), in patients with advanced cancer. J Clin Oncol, in press
46. Piekarz RL et al. (2001) Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 98: 2865-2868
47. Piekarz RL et al. (2004) T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 103: 4636-4643